The Dr. Goodenowe Fight For Health

In Moose Jaw, Saskatchewan, something is being built that does not have an obvious precedent anywhere else in Canada. Across a network of five facilities, residents can access comprehensive biochemical assessments, individualized nutritional guidance, ongoing health monitoring, and community programming, all of it voluntary, all of it grounded in published peer-reviewed science, and all of it offered at no cost to participants. The flagship site at 1350 Lakeview Road occupies a ten-acre campus with an 18,000-square-foot Restorative Health Centre (Lakeview Wellness Centre), and nearby a 25,000-square-foot Community Research Centre is under construction. A 13,000-square-foot Chemistry and Manufacturing located at 30 McKenzie Lane is under construction to be able to produce advanced nutritional products for local and international distribution, and in the Town 'n' Country Mall a street-level information centre and a café called Engage provide walk-in access for anyone who wants to learn more. To date, the operation employs more than fifty people, has enrolled more than 200 Moose Jaw residents, and represents a $100 million investment in the infrastructure, equipment, and programs that make this kind of community-level health support possible.

The people who are using these services represent a cross-section of Moose Jaw. Parents of children on the autism spectrum, some of whom have spent years navigating fragmented services, have enrolled their children in a free Restorative Health in Autism Community Support Program that is open to residents ages two to thirty and requires no referral. Seniors are attending a weekly meal and engagement program designed around nutrition and social connection. Individuals living with complex health concerns, people who in many cases have been told there is nothing more the conventional system can offer them, are working with a support team to understand their own biochemistry and explore science-based options on their own terms. The facilities will house advanced technologies for measuring and improving health and quality of life that most communities this size would never see such as advanced biochemical monitoring, 3T functional MRI, and cardiac imaging, ultrasound, photobiomodulation, ECG, EEG, and advanced vision and hearing, to name a few.

Nothing about this operation is compulsory, and nothing about it is intended to replace medical care. The programs are educational and self-directed, the products involved are commercially available and legally sold, and every participant has chosen to be there of their own accord. There are no outstanding regulatory deficiencies against the organization, no cease-and-desist orders, and no sanctions. What is happening in Moose Jaw is, by every available measure, a legal and compliant operation providing voluntary, science-based health education and support to people who want it and who are making informed decisions about their own wellbeing.

Despite all of this, the right of Moose Jaw residents to access these services is now under sustained attack.

The media campaign

Since June 2025, CBC Saskatchewan has published twelve articles focused on the man behind the Moose Jaw operation, Dr. Dayan Goodenowe, a fourth generation (of six), Saskatchewan resident with a Ph.D. from the University of Alberta and more than 90 peer-reviewed publications in the scientific literature. The series has examined Dr. Goodenowe's commercial activities, the experiences of ALS patients who participated in supplement-based support programs, an FDA warning letter regarding a 2022 study, and claims associated with products sold through Prodrome Sciences, the platform through which more than 3,000 health professionals internationally access Dr. Goodenowe's science-based assessments and nutritional products.

The reporting has prompted investigations by Moose Jaw city police and the province's consumer affairs authority. Dr. Goodenowe has filed a defamation lawsuit against CBC and Leo. That litigation is active.

Questions about health claims and regulatory compliance are legitimate lines of inquiry, and no one involved in the Dr. Goodenowe Moose Jaw operation has suggested otherwise. But twelve articles in eleven months from CBC Saskatchewan, ten of them by one of the province's most prominent investigative reporters, all directed at a single community health operation in a single Saskatchewan city, raises a question the reporting itself has not addressed: who benefits if these programs stop? The practical consequences of a sustained negative media campaign against a community health initiative are not abstract. They affect enrolment, the willingness of health professionals to participate, and the confidence of community members who may want to access these services. They affect the people of Moose Jaw directly, and most acutely, people who have the fewest alternatives.

The science behind the programs

The Moose Jaw operation draws on three decades of research. Dr. Goodenowe earned his B.Sc. in Agricultural Chemistry from the University of Saskatchewan in 1990 and his Ph.D. in Medicine, specializing in Psychiatry, from the University of Alberta in 1994. In 1999, he invented a novel method of complex biological sample analysis, and in 2000 he founded Phenomenome Discoveries Inc. (PDI) in Saskatoon, which over fifteen years became one of Saskatchewan's most prominent biotech ventures.

The published record that emerged from that work includes more than 90 peer-reviewed papers with more than 5,700 citations, spanning Alzheimer's disease, colon cancer, ovarian cancer, pancreatic cancer, and rare genetic diseases. Among the most significant contributions is a landmark 2007 paper identifying plasmalogen deficiency as a factor in Alzheimer's disease, a 2020 study of 1,547 samples from the NIH-funded Alzheimer's Disease Neuroimaging Initiative, and a colon cancer biomarker study involving nearly 6,000 participants with the Saskatchewan Cancer Agency that reported an 86 percent detection rate for colorectal cancer. In May 2011, Saskatchewan became the first province in Canada to license the resulting blood test. Announcing the decision, then-Premier Brad Wall said the technology had "the potential to make a big difference to Saskatchewan people dealing with cancer."

PDI also developed PPI-1011 (U.S. Patent 9,334,235B2), a plasmalogen precursor compound co-invented by Dr. Goodenowe, which became the basis for research into RCDP, a rare and fatal childhood disease. By 2015, an Investigational New Drug application had been filed with the FDA and clinical trial planning was underway. The science behind what is now happening in Moose Jaw is published, cited, and independently verifiable, and the full list of publications is available here.

What the coverage left out

In a March 30, 2026 article, CBC presented Peter Blaney as its primary investor source, framing him as a disillusioned early backer of Dr. Goodenowe's former company, Phenomenome Discoveries Inc. What the article did not mention is the role Blaney played in the events that dismantled that company, or his subsequent connection to the intellectual property that came out of it.

The essential facts are these. At the time the receivership was initiated, Golden Opportunities Fund Inc. (GOFI), a Saskatchewan-based investment fund that was one of Phenomenome's largest backers, carried the company at a $133.5 million enterprise value in its own public filings, and outside consultants had opened sale negotiations at $700 million. According to Dr. Goodenowe's October 2016 written account, Blaney voted on February 19, 2016 to place PDI into full receivership. Barry Markowsky also voted in favour. A partnership that included GOFI subsequently acquired all of PDI's assets. After the receivership, Blaney co-founded GraySpace Therapeutics, a venture connected to the commercialization of PPI-1011, the compound Dr. Goodenowe had co-invented at PDI. His co-founding vehicle was Induran Ventures, the same entity through which he had sat on the Phenomenome board. Markowsky became GraySpace's CEO. PPI-1011 is now being advanced through a Health Canada-approved clinical trial by Med-Life Discoveries, with Phase 1 results published in 2025 (PMID 40083139). Dr. Goodenowe is not listed as an author on that paper.

None of this was disclosed to CBC's readers. Dr. Goodenowe's legal team, in a March 24, 2026 letter to CBC's counsel, urged Leo and his editors to consider carefully the interests of those who may be working through the journalist to promote negative coverage, including those with a financial interest in Dr. Goodenowe's professional and financial ruin. The full financial and corporate history of Phenomenome Discoveries, including the receivership process and the connections between the parties, is documented on this site with links to source material.

The people this affects

The people enrolled in these programs chose to be there. They are Moose Jaw residents who want access to science-based health education, advanced biochemical assessments, and community support, and who are making informed, self-directed decisions about their own wellbeing. That is their right, and this controversy should not be part of their experience.

This site exists because the public record contains information that has not been part of the conversation, and because the people affected by this controversy deserve access to the full picture.

The documents are here. Read the timeline. Read the research. Read the source documents. Decide for yourself.